HASBROUCK HEIGHTS, N.J., May 16, 2012 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (Nasdaq:NYMX) is pleased to announce a symposium and panel discussion on NX-1207, the Company’s Phase 3 drug for benign prostatic hyperplasia (BPH), to be held during the 2012 Annual Meeting of the American Urological Association in Atlanta, GA 3:00 p.m. May 20. The Symposium will be held in the Georgia World Congress Center. The symposium, “Clinical studies of NX-1207: Phase 3 Injectable for BPH,” will be chaired by Ronald Tutrone Jr, MD, FACS of Towson, MD, who will present an overview of NX-1207 and the NX-1207 clinical trials to date, including the three Phase 3 clinical trials currently in progress. Barton H. Wachs, MD, FACS, of Long Beach, CA, will present data from the new studies of the long-term efficacy of NX-1207 treatment. Mohamed Bidair, MD, FACS(C) of San Diego, CA, and Nicholas Franco, MD, FACS of Naples, FL will participate in the panel discussion in the symposium, along with Dr. Tutrone and Dr. Wachs.
